Clinical trials: Ophthalmic Solutions
Presbyopia
Safety and Efficacy Study of BRIMOCHOL™ PF and Carbachol PF in Subjects With Emmetropic Phakic and Pseudophakic Presbyopia
Safety and Efficacy Study of BRIMOCHOL™ PF and Carbachol PF in Subjects With Emmetropic Phakic and Pseudophakic Presbyopia
- Trial name
- NCT05135286
- Testing
- BRIMOCHOL™ PF, Carbachol PF, Vehicle
- Where
- 42 sites in United States
- Volunteers
- 629 people, healthy volunteers welcome
- Sponsor
- Visus Therapeutics
Vision Loss Night, Vision Disorders
OPI-NXYDLD-303 Safety and Efficacy of Phentolamine Ophthalmic Solution in Keratorefractive Surgery Participants With Decreased Mesopic Visual Acuity
The goal of this clinical trial is to learn if Phentolamine Ophthalmic Solution works to treat adults that have had keratorefractive surgery and have decreased visual acuity under mesopic conditions.
- Trial name
- LYNX-3 (NCT07140783)
- Testing
- 0.75% Phentolamine Ophthalmic Solution
- Where
- 20 sites in United States
- Volunteers
- 580 people
- Sponsor
- Opus Genetics, Inc
Blepharitis
Safety and Efficacy Pilot Study of AzaSite® for Four Weeks in Subjects With Blepharitis
The purpose of this study is to evaluate the safety and efficacy of AzaSite® ophthalmic solution, 1% on signs and symptoms of blepharitis.
- Trial name
- NCT00656539
- Testing
- AzaSite®
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Merck Sharp & Dohme LLC
Allergic Conjunctivitis
A Single-Center, Phase 2 Study Evaluating Bilastine Ophthalmic Solution in the CAC® Model
To evaluate the efficacy of Bilastine Ophthalmic Solution (0.2%,0.4%,0.6%) compared to vehicle for the treatment of the signs and symptoms of allergic conjunctivitis
- Trial name
- NCT03231969
- Testing
- Bilastine 0.2%, Bilastine 0.4%, Bilastine 0.6%
- Where
- United States
- Volunteers
- 121 people
- Sponsor
- Faes Farma, S.A.
Dry Eye Disease, Dry Eye Sensation
Study to Evaluating PRO-240 Ophthalmic Solution Compared to Optive®
This is a phase I clinical study to evaluating safety and tolerability of PRO-240 ophthalmic solution through the incidence of unexpected adverse events, as well as through changes in Best Corrected Visual Acuity (BCVA), and the…
- Conditions
- Dry Eye Disease, Dry Eye Sensation, Ocular Surface Disease
- Trial name
- NCT06375343
- Testing
- PRO-240, Optive®
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Laboratorios Sophia S.A de C.V.
Diabetic Retinopathy
Expansion of Integrated AI Solution for Diabetic Retinopathy Screening in Thailand
Efficiency and effectiveness of real-world diabetic retinopathy screening by artificial intelligent (AI) are limited. Investigators will implement AI for diabetic retinopathy screening in 13 health districts in Thailand and…
- Trial name
- NCT05527535
- Testing
- Diabetic retinopathy screening by artificial intelligence, Diabetic retinopathy screening by healthcare personnel
- Volunteers
- 34,500 people
- Sponsor
- Department of Medical Services Ministry of Public Health of Thailand
Graft-versus-host-disease, Ocular Graft-versus-host Disease
The Effects and Safety of 5% Lifitegrast Ophthalmic Solution in Subjects With Dry Eye Disease in Ocular Graft-versus-Host Disease
The objective of this study is to evaluate the clinical efficacy of 5% lifitegrast ophthalmic solution in subjects with dry eye disease secondary to ocular Graft-versus-Host Disease compared to placebo.
- Trial name
- NCT04792580
- Testing
- Lifitegrast 5% Ophthalmic Solution
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Richard W Yee, MD
Mydriasis, Dilation
Safety and Efficacy of Nyxol (0.75% Phentolamine Ophthalmic Solution) to Reverse Pharmacologically-Induced Mydriasis (MIRA-3)
The objectives of this study are: To evaluate the efficacy of Nyxol to expedite the reversal of pharmacologically-induced mydriasis across multiple mydriatic agents with an emphasis on phenylephrine To evaluate the efficacy of…
- Trial name
- MIRA-3 (NCT05134974)
- Testing
- Phentolamine Ophthalmic Solution 0.75%, Phentolamine Ophthalmic Solution Vehicle
- Where
- 15 sites in United States
- Volunteers
- 368 people, healthy volunteers welcome
- Sponsor
- Opus Genetics, Inc
Normal Volunteers
Formulation Comparison in Normal Volunteers
This is a double-masked, single-center, crossover study in which normal volunteers will be randomized to receive one of two formulations of 0.5% AR-12286 Ophthalmic Solution for 8 days.
- Trial name
- NCT01250197
- Testing
- AR-12286
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Aerie Pharmaceuticals
Open-Angle Glaucoma, Ocular Hypertension
Safety and Efficacy Study of DE-104 Ophthalmic Solution to Treat Open-Angle Glaucoma or Ocular Hypertension
To investigate the dose-response relationship of DE-104 ophthalmic solution in lowering intraocular pressure (IOP) in subjects with Primary Open-Angle Glaucoma or Ocular Hypertension
- Trial name
- NCT00657579
- Testing
- DE-104 ophthalmic solution, low concentration, DE-104 ophthalmic solution, medium concentration, DE-104 ophthalmic solution, high concentration
- Where
- Japan
- Sponsor
- Santen Pharmaceutical Co., Ltd.
Corneal Epithelial Disorders
Safety and Efficacy of SJP-0035 Ophthalmic Solution in Patients With Moderate to Severe Corneal Epithelial Disorders
The purpose of this study is to determine whether SJP-0035 ophthalmic solution is effective in promoting corneal epithelial wound healing in conditions associated with corneal epithelial disorders.
- Trial name
- NCT02929823
- Testing
- High Dose SJP-0035 Ophthalmic Solution, Low Dose SJP-0035 Ophthalmic Solution, Vehicle of SJP-0035 Ophthalmic solution
- Where
- 19 sites in United States
- Volunteers
- 130 people
- Sponsor
- Senju Pharmaceutical Co., Ltd.
Dry Eye Disease
A Study to Investigate the Effect of 0.003% AR-15512 on Subjects With Dry Eye Disease
The purpose of this study is to evaluate the effect of AR-15512 ophthalmic solution 0.003% (0.003% AR-15512) on ocular surface characteristics of subjects with dry eye disease (DED).
- Trial name
- NCT06544694
- Testing
- 0.003% AR-15512 ophthalmic solution, Artificial Tears
- Where
- 4 sites in United States
- Volunteers
- 80 people
- Sponsor
- Alcon Research
Glaucoma
The Efficacy of Citicoline in Eyedrops (OMK1) in Reducing the Progression of Glaucoma
Double-blind study (OMK1 vs. Placebo) A total of 90 patients, 30 per center, will be the study sample. The study will include patients with Primary Open angle Glaucoma (glaucoma or pseudoexfoliation) with a loss of visual field…
- Trial name
- NCT04020705
- Testing
- Citicoline eye drops (OMK1)
- Volunteers
- 90 people
- Sponsor
- Istituto di Ricerca Neuroftalmologia S.r.l.
Keratoconus, Pellucid Marginal Corneal Degeneration
Safety and Effectiveness of the PXL-Platinum 330 System for CXL Using Riboflavin Solution
Safety and Effectiveness of the PXL-Platinum 330 System for Corneal Collagen Cross-linking in Eyes With Corneal Thinning Conditions
- Conditions
- Keratoconus, Pellucid Marginal Corneal Degeneration, Corneal Degeneration, Corneal Ectasia
- Trial name
- NCT04177082
- Testing
- PXL-330 Platinum device for crosslinking with Peschke riboflavin solution
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- Cornea Associates of Texas
Open Angle Glaucoma or Ocular Hypertension
A Phase III Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution Compared With Latanoprost Ophthalmic Solution in Subjects With OAG or OHT
The purpose of this study is to investigate the intraocular pressure-lowering effect and the safety of DE-117 ophthalmic solution compared with Latanoprost ophthalmic solution in subjects with open angle glaucoma or ocular…
- Trial name
- NCT02981446
- Testing
- DE-117, Latanoprost ophthalmic solution
- Where
- Singapore
- Volunteers
- 370 people
- Sponsor
- Santen Pharmaceutical Co., Ltd.
Post Inflammtory Erythema, Acne Vulgaris
Efficacy of 0.5% Topical Timolol Eye Drops in the Treatment of Post-Inflammatory Erythema Following Acne Vulgaris
Post-inflammatory erythema (PIE) is a common sequela of acne vulgaris, characterized by persistent erythematous macules resulting from superficial vascular dilation.
- Conditions
- Post Inflammtory Erythema, Acne Vulgaris, Erythema
- Trial name
- NCT07474883
- Testing
- Timolol 0.5% Ophthalmic Solution, Intense Pulsed Light
- Where
- Vietnam
- Volunteers
- 60 people
- Sponsor
- Pham Ngoc Thach University of Medicine
Dry Eye
A Study to Evaluate the Safety and Efficacy of VSJ-110 Compared to Placebo in the Treatment of Dry Eye
The purpose of this study is to determine the safety and efficacy of VSJ-110 compared to placebo in the treatment of dry eye.
- Trial name
- NCT06296966
- Testing
- VSJ-110
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Vanda Pharmaceuticals
Conjunctivitis, Bacterial
Efficacy and Safety of T1225 1.5% Versus Tobramycin 0.3 % in the Treatment of Purulent Bacterial Conjunctivitis
To demonstrate the efficacy of T1225 1.5% eye drops, in comparison to reference product, for the treatment of purulent bacterial conjunctivitis, and to assess the safety
- Trial name
- NCT00357773
- Testing
- Azithromycin (T1225)
- Sponsor
- Laboratoires Thea
Bacterial Conjunctivitis
Safety and Efficacy of PRO-157 vs Moxifloxacin vs Gatifloxacin in Patients With Bacterial Conjunctivitis (Pazufloxacin)
A randomized, double blind, phase II multicenter trial with the objective of assess the safety and efficacy of the PRO-157 ophthalmic solution in three different dosing regimens, versus Moxifloxacin, versus Gatifloxacin in…
- Trial name
- Pazufloxacin (NCT02980523)
- Testing
- PRO-157, Vigamox, Zymar®
- Where
- Mexico
- Volunteers
- 150 people
- Sponsor
- Laboratorios Sophia S.A de C.V.
Adult Patients Undergoing Phacoemulsification With Topical Anesthesia
Comparison Between 2% Lidocaine Gel and 5% Tetracaine Eye Drop as Topical Anesthesia in Phacoemulsification
This study aimed to compare the efficacy between 2% lidocaine gel vs 0.5% tetracaine eye drop as topical anesthesia in phacoemulsification
- Trial name
- NCT03143452
- Testing
- lidocaine gel, tetracaine eye drop
- Where
- Indonesia
- Volunteers
- 72 people
- Sponsor
- Universitas Indonesia
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.